X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, GENFIT will advance Celloram’s first-in-class inflammasome inhibitor, CLM-022, a triterpenoid derivative that targets the inflammasome machinery, in liver disease indications.
Lead Product(s): CLM-022
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CLM-022
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Celloram
Deal Size: $175.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 31, 2023
Details:
GFT505 (elafibranor) is a novel, oral, once-daily, dual peroxisome activated receptor (PPAR) alpha/delta (α,δ) agonist, currently under investigation as a treatment for patients with PBC, a rare liver disease.
Lead Product(s): Elafibranor
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GFT505
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Ipsen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2023
Details:
Under the agreement, GENFIT has gained the exclusive worldwide rights of SRT-015, a highly optimized, first-in-class ASK1 inhibitor being developed in acute-on-chronic liver failure (ACLF), from Seal Rock Therapeutics.
Lead Product(s): SRT-015
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SRT-015
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Seal Rock Therapeutics
Deal Size: $106.8 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 31, 2023
Details:
VS-01, is a first-in-class innovative liposomal-based therapeutic product candidate currently in clinical development as a potential first-line therapy for the timely recovery of ACLF and UCD.
Lead Product(s): VS-01
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VS-01
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Versantis
Deal Size: $107.6 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 19, 2022
Details:
GNS561 (ezurpimtrostat) is a PPT-1 (Palmitoyl Protein Thioesterase-1) inhibitor that blocks autophagy. Autophagy is activated in tumor cells in response to certain conditions, due to a tumor cell growth in advanced cancers.
Lead Product(s): Ezurpimtrostat
Therapeutic Area: Oncology Product Name: GNS561
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
The agreement gives Ipsen exclusive worldwide* license to develop, manufacture and commercialize GENFIT’s GFT505, an investigational treatment elafibranor, for people living with Primary Biliary Cholangitis (PBC).
Lead Product(s): Elafibranor
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GFT505
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ipsen
Deal Size: $583.0 million Upfront Cash: $137.7 million
Deal Type: Licensing Agreement December 17, 2021
Details:
Through the acquisition of exclusive rights from Genoscience Pharma to develop and commercialize the investigational treatment GNS561 in cholangiocarcinoma in the United States, Canada and Europe, including the United Kingdom and Switzerland.
Lead Product(s): Ezurpimtrostat
Therapeutic Area: Oncology Product Name: GNS561
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Genoscience Pharma
Deal Size: $3.4 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 17, 2021
Details:
Company presents Elafibranor, dual agonism of peroxisome proliferator-activated alpha/delta receptors found to be efficacious in the treatment of PBC, a rare liver disease.
Lead Product(s): Elafibranor
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GFT505
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2021
Details:
GENFIT is launching a clinical program with nitazoxanide (NTZ) in this disease. A Phase 1 study to evaluate pharmacokinetics and pharmacodynamics in patients with varying degrees of hepatic impairment is expected to start in 4Q21 with clinical data expected end of 2022.
Lead Product(s): Nitazoxanide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2021
Details:
ELATIVE™ is a randomized, double blind, placebo-controlled, global multicenter Phase 3 study evaluating the efficacy and safety of elafibranor, a dual PPAR alpha and delta agonist, in PBC.
Lead Product(s): Elafibranor
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GFT505
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
